Home LiteratureArticle Details
PMID: 17476348 Published · ppublish English Journal Article Review

Development of TLR9 agonists for cancer therapy.

The Journal of clinical investigation ·Vol. 117 ·No. 5 ·2007-05-00 ·Pages 1184-94

Krieg AM

Abstract

In vertebrates, the TLRs are a family of specialized immune receptors that induce protective immune responses when they detect highly conserved pathogen-expressed molecules. Synthetic agonists for several TLRs, including TLR3, TLR4, TLR7, TLR8, and TLR9, have been or are being developed for the treatment of cancer. TLR9 detects the unmethylated CpG dinucleotides prevalent in bacterial and viral DNA but not in vertebrate genomes. As discussed in this Review, short synthetic oligodeoxynucleotides containing these immune stimulatory CpG motifs activate TLR9 in vitro and in vivo, inducing innate and adaptive immunity, and are currently being tested in multiple phase II and phase III human clinical trials as adjuvants to cancer vaccines and in combination with conventional chemotherapy and other therapies.

MeSH Terms
Animals Antineoplastic Agents/chemical synthesis,pharmacology Drug Design Humans Neoplasms/drug therapy,immunology,metabolism Toll-Like Receptor 9/agonists
Chemicals
Antineoplastic Agents Toll-Like Receptor 9
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Krieg Arthur M
Coley Pharmaceutical Group, 93 Worcester Street, Wellesley, MA 02481, USA. [email protected]
References (118)
118 references, click to expand
  1. A Toll-like receptor recognizes bacterial DNA.
    Nature. 2000 Dec 7;408(6813):740-5 PMID: 11130078
  2. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
    Cancer Res. 2001 May 1;61(9):3689-97 PMID: 11325840
  3. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology.
    Nat Immunol. 2001 Dec;2(12):1144-50 PMID: 11713464
  4. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide.
    J Immunol. 2002 Feb 1;168(3):1212-8 PMID: 11801657
  5. In vivo manipulation of dendritic cells to induce therapeutic immunity.
    Blood. 2002 Mar 1;99(5):1676-82 PMID: 11861283
  6. Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity.
    J Immunol. 2002 Jun 15;168(12):6099-105 PMID: 12055220
  7. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.
    J Immunol. 2002 Jul 1;169(1):350-8 PMID: 12077264
  8. Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation.
    J Exp Med. 2002 Jul 15;196(2):269-74 PMID: 12119352
  9. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.
    Cancer Immun. 2004 May 19;4:4 PMID: 15149168
  10. Cellular immunity in breast cancer patients completing taxane treatment.
    Clin Cancer Res. 2004 May 15;10(10):3401-9 PMID: 15161695
  11. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.
    Breast Cancer Res. 2004;6(4):R275-83 PMID: 15217493
  12. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.
    Expert Opin Biol Ther. 2004 Jul;4(7):1129-38 PMID: 15268679
  13. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
    Cancer Res. 2004 Aug 1;64(15):5407-14 PMID: 15289349
  14. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine.
    Vaccine. 2004 Aug 13;22(23-24):3136-43 PMID: 15297066
  15. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner.
    Eur J Immunol. 2004 Sep;34(9):2541-50 PMID: 15307186
  16. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity.
    Cancer Res. 2004 Aug 15;64(16):5850-60 PMID: 15313929
  17. Cancer immunotherapy: moving beyond current vaccines.
    Nat Med. 2004 Sep;10(9):909-15 PMID: 15340416
  18. Murine plasmacytoid dendritic cells induce effector/memory CD8+ T-cell responses in vivo after viral stimulation.
    Blood. 2004 Sep 15;104(6):1808-15 PMID: 15166034
  19. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.
    Immunology. 2004 Oct;113(2):212-23 PMID: 15379982
  20. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells.
    J Immunol. 2004 Oct 1;173(7):4433-42 PMID: 15383574
  21. Toll-like receptor control of the adaptive immune responses.
    Nat Immunol. 2004 Oct;5(10):987-95 PMID: 15454922
  22. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
    Cancer Res. 1993 Nov 1;53(21):5176-80 PMID: 8221654
  23. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.
    Blood. 1997 Apr 15;89(8):2994-8 PMID: 9108420
  24. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.
    Nat Med. 1997 Aug;3(8):849-54 PMID: 9256274
  25. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants.
    Eur J Immunol. 1997 Sep;27(9):2340-4 PMID: 9341778
  26. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity.
    J Exp Med. 1997 Nov 17;186(10):1623-31 PMID: 9362523
  27. Toxicology of antisense therapeutics.
    Toxicol Appl Pharmacol. 2004 Nov 15;201(1):66-83 PMID: 15519609
  28. CD4+ CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1.
    J Virol. 2004 Dec;78(23):13082-9 PMID: 15542660
  29. Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response.
    Vaccine. 2004 Dec 16;23(5):615-22 PMID: 15542181
  30. Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells.
    J Immunol. 2004 Dec 15;173(12):7249-58 PMID: 15585847
  31. Imiquimod for the treatment of skin cancer.
    Dermatol Clin. 2005 Jan;23(1):151-64, vii PMID: 15620626
  32. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study.
    J Clin Immunol. 2004 Nov;24(6):693-701 PMID: 15622454
  33. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.
    Blood. 2005 Jan 15;105(2):489-95 PMID: 15358617
  34. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy.
    Clin Cancer Res. 2005 Jan 1;11(1):361-9 PMID: 15671567
  35. Augmenting the potency of breast cancer vaccines: combined modality immunotherapy.
    Breast Dis. 2004;20:13-24 PMID: 15687703
  36. Variegation of the immune response with dendritic cells and pathogen recognition receptors.
    J Immunol. 2005 Mar 1;174(5):2457-65 PMID: 15728447
  37. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
    J Immunol. 2005 Mar 1;174(5):2591-601 PMID: 15728465
  38. In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumor-associated self antigens and induces potent antitumor immunity.
    J Immunol. 2005 Mar 1;174(5):2645-52 PMID: 15728471
  39. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.
    J Leukoc Biol. 2005 Mar;77(3):378-87 PMID: 15582984
  40. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
    Clin Cancer Res. 2005 Feb 15;11(4):1490-9 PMID: 15746051
  41. CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma.
    World J Gastroenterol. 2005 Feb 28;11(8):1220-4 PMID: 15754409
  42. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors.
    Annu Rev Immunol. 2005;23:275-306 PMID: 15771572
  43. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.
    J Clin Invest. 2005 Mar;115(3):739-46 PMID: 15696196
  44. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.
    Blood. 2005 Apr 1;105(7):2862-8 PMID: 15591121
  45. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma.
    J Immunother. 2006 Jul-Aug;29(4):367-80 PMID: 16799332
  46. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9.
    Mol Cancer Ther. 2006 Jun;5(6):1585-92 PMID: 16818518
  47. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity.
    Trends Immunol. 2006 Aug;27(8):352-7 PMID: 16807108
  48. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.
    Cancer Res. 2006 Jul 15;66(14):7285-92 PMID: 16849578
  49. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.
    J Immunol. 2006 Aug 1;177(3):1670-8 PMID: 16849476
  50. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma.
    J Pediatr Surg. 2006 Aug;41(8):1361-8 PMID: 16863838
  51. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer.
    Vaccine. 2006 Aug 28;24(35-36):6155-62 PMID: 16876291
  52. Immunomodulation of the melanoma sentinel lymph node: a novel adjuvant therapeutic option.
    Immunobiology. 2006;211(6-8):651-61 PMID: 16920504
  53. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody.
    J Exp Med. 2002 Aug 19;196(4):541-9 PMID: 12186845
  54. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
    Science. 2002 Oct 25;298(5594):850-4 PMID: 12242449
  55. Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.
    Immunol Rev. 2002 Oct;188:81-96 PMID: 12445283
  56. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Cancer Res. 2002 Dec 15;62(24):7234-40 PMID: 12499264
  57. Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation.
    J Exp Med. 2003 Jan 6;197(1):101-9 PMID: 12515817
  58. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
    Cancer Res. 2003 Jan 15;63(2):394-9 PMID: 12543793
  59. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
    Eur J Immunol. 2002 Nov;32(11):3235-45 PMID: 12555669
  60. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells.
    Science. 2003 Feb 14;299(5609):1033-6 PMID: 12532024
  61. Toll-like receptors.
    Annu Rev Immunol. 2003;21:335-76 PMID: 12524386
  62. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets.
    J Immunol. 2003 Mar 15;170(6):3059-64 PMID: 12626561
  63. Interferon-producing cells fail to induce proliferation of naive T cells but can promote expansion and T helper 1 differentiation of antigen-experienced unpolarized T cells.
    J Exp Med. 2003 Apr 7;197(7):899-906 PMID: 12668648
  64. Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity.
    Blood. 2003 May 1;101(9):3520-6 PMID: 12511409
  65. A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant.
    Vaccine. 2003 Jun 2;21(19-20):2461-7 PMID: 12744879
  66. Role of Toll-like receptors in costimulating cytotoxic T cell responses.
    Eur J Immunol. 2003 Jun;33(6):1465-70 PMID: 12778463
  67. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Cancer Res. 2003 Jun 15;63(12):3281-8 PMID: 12810660
  68. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides.
    Clin Cancer Res. 2003 Jul;9(7):2693-700 PMID: 12855649
  69. CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo.
    J Exp Med. 2003 Jul 21;198(2):259-66 PMID: 12874259
  70. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
    Cancer Res. 2003 Aug 1;63(15):4490-6 PMID: 12907622
  71. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma.
    Clin Cancer Res. 2003 Aug 1;9(8):3105-14 PMID: 12912962
  72. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity.
    J Immunol. 2003 Oct 15;171(8):3941-6 PMID: 14530311
  73. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice.
    J Immunol. 2003 Dec 1;171(11):5908-12 PMID: 14634101
  74. Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin.
    Clin Cancer Res. 2003 Dec 15;9(17):6516-22 PMID: 14695156
  75. TLR9 signals after translocating from the ER to CpG DNA in the lysosome.
    Nat Immunol. 2004 Feb;5(2):190-8 PMID: 14716310
  76. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.
    Curr Oncol Rep. 2004 Mar;6(2):88-95 PMID: 14751085
  77. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
    Eur J Immunol. 2004 Feb;34(2):336-44 PMID: 14768038
  78. CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro.
    Blood. 2004 Mar 15;103(6):2162-9 PMID: 14630815
  79. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
    Semin Cancer Biol. 2003 Dec;13(6):461-72 PMID: 15001165
  80. Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts.
    Eur J Cancer. 2004 May;40(8):1275-81 PMID: 15110894
  81. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection.
    Cancer Res. 2005 Apr 15;65(8):3437-46 PMID: 15833879
  82. Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs.
    Immunity. 2005 Apr;22(4):467-77 PMID: 15845451
  83. Immunotherapy and chemotherapy--a practical partnership.
    Nat Rev Cancer. 2005 May;5(5):397-405 PMID: 15864281
  84. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.
    J Exp Med. 2005 May 16;201(10):1591-602 PMID: 15883172
  85. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft.
    Cancer Res. 2005 Jul 15;65(14):6388-93 PMID: 16024642
  86. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.
    AIDS. 2005 Sep 23;19(14):1473-9 PMID: 16135900
  87. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.
    Blood. 2005 Sep 15;106(6):2018-25 PMID: 15914560
  88. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy.
    Cancer Res. 2005 Sep 15;65(18):8059-64 PMID: 16166275
  89. Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses.
    Cancer Res. 2005 Sep 15;65(18):8479-86 PMID: 16166328
  90. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling.
    J Immunol. 2005 Nov 1;175(9):5601-5 PMID: 16237046
  91. Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation.
    J Exp Med. 2005 Nov 21;202(10):1333-9 PMID: 16301743
  92. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
    J Clin Oncol. 2005 Dec 10;23(35):8950-8 PMID: 16061910
  93. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA.
    Nat Immunol. 2006 Jan;7(1):40-8 PMID: 16286919
  94. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects.
    J Immunol. 2006 Jan 1;176(1):309-18 PMID: 16365423
  95. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
    Eur J Immunol. 2006 Jan;36(1):12-20 PMID: 16323249
  96. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response.
    Immunity. 2006 Jan;24(1):93-103 PMID: 16413926
  97. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Clin Cancer Res. 2006 Jan 15;12(2):577-83 PMID: 16428503
  98. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma.
    Neuro Oncol. 2006 Jan;8(1):60-6 PMID: 16443949
  99. Toll-like receptor 2 controls expansion and function of regulatory T cells.
    J Clin Invest. 2006 Feb;116(2):485-94 PMID: 16424940
  100. Tolerance induction by transcutaneous immunization through ultraviolet-irradiated skin is transferable through CD4+CD25+ T regulatory cells and is dependent on host-derived IL-10.
    J Immunol. 2006 Feb 15;176(4):2635-44 PMID: 16456026
  101. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.
    Immunity. 2006 Feb;24(2):179-89 PMID: 16473830
  102. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines.
    J Immunol. 2006 Mar 1;176(5):2722-9 PMID: 16493027
  103. Translating innate immunity into immunological memory: implications for vaccine development.
    Cell. 2006 Feb 24;124(4):849-63 PMID: 16497593
  104. Antitumor efficacy of the novel chemotherapeutic agent coramsine is potentiated by cotreatment with CpG-containing oligodeoxynucleotides.
    J Immunother. 2006 Mar-Apr;29(2):134-42 PMID: 16531814
  105. Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer.
    Int J Cancer. 2006 Jun 1;118(11):2790-5 PMID: 16388515
  106. Regulatory T cells, tumour immunity and immunotherapy.
    Nat Rev Immunol. 2006 Apr;6(4):295-307 PMID: 16557261
  107. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer.
    J Immunol. 2006 Jun 1;176(11):6624-30 PMID: 16709820
  108. Therapeutic potential of Toll-like receptor 9 activation.
    Nat Rev Drug Discov. 2006 Jun;5(6):471-84 PMID: 16763660
  109. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.
    J Immunother. 2006 Sep-Oct;29(5):558-68 PMID: 16971811
  110. Innate immune recognition of, and regulation by, DNA.
    Trends Immunol. 2006 Nov;27(11):525-32 PMID: 16979939
  111. Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth.
    Cancer Res. 2006 Nov 1;66(21):10497-504 PMID: 17079471
  112. High accumulation of T regulatory cells prevents the activation of immune responses in aged animals.
    J Immunol. 2006 Dec 15;177(12):8348-55 PMID: 17142731
  113. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma.
    J Clin Oncol. 2006 Dec 20;24(36):5716-24 PMID: 17179105
  114. Calreticulin exposure dictates the immunogenicity of cancer cell death.
    Nat Med. 2007 Jan;13(1):54-61 PMID: 17187072
  115. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
    Vaccine. 1999 Nov 12;18(7-8):597-603 PMID: 10547417
  116. CpG DNA induces stronger immune responses with less toxicity than other adjuvants.
    Vaccine. 2000 Mar 6;18(17):1755-62 PMID: 10699323
  117. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    J Immunol. 2000 Jul 1;165(1):539-47 PMID: 10861094
  118. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells.
    J Immunol. 2000 Dec 1;165(11):6244-51 PMID: 11086059
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
DOI
10.1172/JCI31414
Email
[email protected]
Published
2007-05-00
Pages
1184-94
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC1857270
Subset
IM
External Links
PubMed source DOI: 10.1172/JCI31414 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2